C4 Therapeutics, Inc.
BIFUNCTIONAL MOLECULES THAT DEGRADE EGFR
Last updated:
Abstract:
The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.
Status:
Application
Type:
Utility
Filling date:
4 Aug 2020
Issue date:
19 Nov 2020